Product Description
Mechanisms of Action: DNA Adduct
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Nasal,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Denmark | European Medicines Agency | Finland | Iceland | Ireland | Lithuania | Pakistan | Peru | Poland | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|